Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

Lee S Rosen1*, Lara Lipton2, Timothy J Price3, Neil D Belman4, Ralph V Boccia5, Herbert I Hurwitz6, Joe J Stephenson Jr7, Lori J Wirth8, Sheryl McCoy9, Yong-jiang Hei10, Cheng-Pang Hsu11 and Niall C Tebbutt12

Author Affiliations

1 Department of Medicine, University of California Los Angeles, Santa Monica, CA, USA

2 Western Hospital, Footscray, and Royal Melbourne Hospital, Parkville, VIC, Australia

3 The Queen Elizabeth Hospital, University of Adelaide School of Medicine, Woodville, SA, Australia

4 Oncology Hematology of Lehigh Valley, Bethlehem, PA, USA

5 Center for Cancer and Blood Disorders, Bethesda, MD, USA

6 Duke University Medical Center, Durham, NC, USA

7 Cancer Centers of the Carolinas, Greenville, SC, USA

8 Dana-Farber Cancer Institute and Massachusetts General Hospital, Boston, MA, USA

9 Department of Biostatistics, Amgen Inc., South San Francisco, CA, USA

10 Department of Oncology, Amgen Inc., Thousand Oaks, CA, USA

11 Department of Pharmacokinetics & Drug Metabolism, Amgen Inc, Thousand Oaks, CA, USA

12 Ludwig Oncology Unit, Austin Hospital, Heidelberg, VIC, Australia

For all author emails, please log on.

BMC Cancer 2013, 13:242  doi:10.1186/1471-2407-13-242

Published: 16 May 2013



Gallbladder toxicity, including cholecystitis, has been reported with motesanib, an orally administered small-molecule antagonist of VEGFRs 1, 2 and 3; PDGFR; and Kit. We assessed effects of motesanib on gallbladder size and function.


Patients with advanced metastatic solid tumors ineligible for or progressing on standard-of-care therapies with no history of cholecystitis or biliary disease were randomized 2:1:1 to receive motesanib 125 mg once daily (Arm A); 75 mg twice daily (BID), 14-days-on/7-days-off (Arm B); or 75 mg BID, 5-days-on/2-days-off (Arm C). Primary endpoints were mean change from baseline in gallbladder size (volume by ultrasound; independent review) and function (ejection fraction by CCK-HIDA; investigator assessment).


Forty-nine patients received ≥1 dose of motesanib (Arms A/B/C, n = 25/12/12). Across all patients, gallbladder volume increased by a mean 22.2 cc (from 38.6 cc at baseline) and ejection fraction decreased by a mean 19.2% (from 61.3% at baseline) during treatment. Changes were similar across arms and appeared reversible after treatment discontinuation. Three patients had cholecystitis (grades 1, 2, 3, n = 1 each) that resolved after treatment discontinuation, one patient developed grade 3 acute cholecystitis requiring cholecystectomy, and two patients had other notable grade 1 gallbladder disorders (gallbladder wall thickening, gallbladder dysfunction) (all in Arm A). Two patients developed de novo gallstones during treatment. Twelve patients had right upper quadrant pain (Arms A/B/C, n = 8/1/3). The incidence of biliary “sludge” in Arms A/B/C was 39%/36%/27%.


Motesanib treatment was associated with increased gallbladder volume, decreased ejection fraction, biliary sludge, gallstone formation, and infrequent cholecystitis.

Trial registration NCT00448786